US 8546433
Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
granted A61KA61K31/4196A61K31/502
Quick answer
US patent 8546433 (Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/4196, A61K31/502, A61K33/243, A61K45/06